Celgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic Syndromes
30 Abril 2015 - 6:35AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutic candidates that regulate
cellular growth and repair, today announced that Acceleron and its
collaboration partner, Celgene Corporation, plan to initiate a
Phase 3 program with luspatercept in myelodysplastic syndromes and
beta-thalassemia by year-end 2015. The companies will continue to
develop sotatercept for patients with chronic kidney disease.
Preliminary data from the ongoing phase 2 clinical trial of
luspatercept in patients with lower risk MDS will be presented by
Uwe Platzbecker, M.D., University Hospital in Dresden, Germany, in
the oral session “Best of Clinical Trials II” at the MDS Foundation
13th International Symposium on Myelodysplastic Syndromes on
Saturday May 2, 2015, at 10:30 AM (EDT) at the Washington Marriott
Wardman Park Hotel in Washington, D.C.
About Luspatercept
Luspatercept is a modified activin receptor type IIB fusion
protein that acts as a ligand trap for members in the Transforming
Growth Factor-Beta (TGF-β) superfamily involved in the late stages
of erythropoiesis (red blood cell production). Luspatercept
regulates late-stage erythrocyte (red blood cell) precursor cell
differentiation and maturation. This mechanism of action is
distinct from that of erythropoietin (EPO), which stimulates the
proliferation of early-stage erythrocyte precursor cells. Acceleron
and Celgene are jointly developing luspatercept as part of a global
collaboration. Luspatercept is currently in phase 2 clinical trials
in patients with beta-thalassemia and in patients with
myelodysplastic syndromes. For more information, please visit
www.clinicaltrials.gov.
About Myelodysplastic Syndromes
MDS are a heterogeneous group of hematologic malignancies of the
bone marrow commonly leading to severe and chronic anemia due to
ineffective erythropoiesis. The National Cancer Institute estimates
that more than 10,000 people are diagnosed with MDS in the United
States each year. Patients with MDS have a hypercellular bone
marrow with various dysplastic changes of the cells that are also
seen in peripheral blood, resulting in cytopenias (low blood cell
counts) and an increased risk of progression to acute myeloid
leukemia. Nearly all MDS patients suffer from anemia. The anemia in
MDS is characterized by high endogenous levels of EPO driving an
abundance of early stage red blood cell precursors and an inability
of these precursor cells to properly differentiate into healthy,
functional red blood cells. Many patients are therefore
unresponsive to the administration of erythropoietin to correct the
resulting anemia and instead require red blood cell transfusions,
which can increase the risk of infection and iron-overload related
toxicities.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
therapeutic candidates that regulate cellular growth and repair.
The company is a leader in understanding the biology of the TGF-β
protein superfamily, a large and diverse group of molecules that
are key regulators in the growth and repair of tissues throughout
the human body, and in targeting these pathways to develop
important new medicines. Acceleron has built a highly productive
R&D platform that has generated innovative clinical and
preclinical protein therapeutic candidates with novel mechanisms of
action. These therapeutic candidates have the potential to
significantly improve clinical outcomes for patients with cancer
and rare diseases.
For more information, please visit
www.acceleronpharma.com.
Acceleron Pharma Inc.Kevin F. McLaughlin, 617-649-9204Senior
Vice President and Chief Financial OfficerorMedia contact:Suda
Communications LLCMaureen L. Suda, 585-387-9248
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024